Get started
Author

Paula L. Kosasih

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
2015 · D Sommermeyer, M Hudecek, et al. · Leukemia · 864
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
2013 · Michael Hudecek, Maria-Teresa Lupo-Stanghellini, et al. · Clinical Cancer Research · 541
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
2014 · Michael Hudecek, Daniel Sommermeyer, et al. · Cancer Immunology Research · 529
PDF
Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
2016 · Ashwini Balakrishnan, Tracy Goodpaster, et al. · Clinical Cancer Research · 223
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2014 · Carolina Berger, Daniel Sommermeyer, et al. · Cancer Immunology Research · 172
PDF
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
2019 · Ashwini Balakrishnan, Anusha Rajan, et al. · Clinical Cancer Research · 60
Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy
2016 · Lingfeng Liu, Daniel Sommermeyer, et al. · Nature Biotechnology · 60
Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
2014 · S Carolina Berger, Daniel Sommermeyer, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
The Non-Signaling Extracellular Spacer Domain of CD19-Specific Chimeric Antigen Receptors Is Decisive for in Vivo Anti-Tumor Activity
2012 · Michael Hudecek, Anne Silva, et al. · Blood · 3
Data from Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
2023 · Ashwini Balakrishnan, Tracy Goodpaster, et al. · 1
Naive CD4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ ROR1-CAR T Cells
2011 · Michael Hudecek, Maria-Teresa Lupo-Stanghellini, et al. · Blood · 1
5.53 The Anti-Tumor Reactivity of ROR1-CAR Modified T Cells Depends on the Targeted Epitope, CAR-Affinity and Design of the CAR Extracellular Domain
2011 · Michael Hudecek, Maria-Teresa Lupo-Stanghellini, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Supplementary Figure S2 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
PDF
Supplementary Figure S5 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
Supplementary Figure Legends from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
PDF
Supplementary Figure S1 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
PDF
Supplementary Figure S3 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
Supplementary Figure S4 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
PDF
Data from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
Data from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
2023 · Michael Hudecek, Daniel Sommermeyer, et al.
Supplementary Figure S5 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
PDF
Supplementary Figure S4 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
2023 · Carolina Berger, Daniel Sommermeyer, et al.
Supplementary Figure 1 from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
2023 · Michael Hudecek, Daniel Sommermeyer, et al.
Supplemental Materials and Methods from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
2023 · Michael Hudecek, Daniel Sommermeyer, et al.
Supplementary Figure 2 from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
2023 · Michael Hudecek, Daniel Sommermeyer, et al.
Works count: 53
Citation count: 2,458
H-index: 7
I10-index: 7
Year
Topic
Type